Helicobacter pylori and inflammation

Current Pharmaceutical Design

Volumn 16, Issue 38, 2010, Pages 4225-4236

  Ruggiero, Paolo ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Colonization; Gastric cancer; Gastric disease; Helicobacter pylori; Inflammation; Virulence

Indexed keywords

BACTERIAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NEUTROPHIL ACTIVATING PROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREASE; VACUOLATING TOXIN;

ANTIGEN RECOGNITION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHRONIC GASTRITIS; CROSS REACTION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMACH CANCER; T LYMPHOCYTE; TH1 CELL;

ANIMALS; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH DISEASES;

EID: 79951716068     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519075     Document Type: Article

References (181)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5.
2. Goodwin CS, Armstrong JA, Chilvers T, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter rnustelae comb. nov., respectively. Int J Syst Bacteriol 1989; 39: 397-405.
3. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39: 353-65.
4. Okoli AS, Menard A, Mendz GL. Helicobacter spp. other than Helicobacter pylori. Helicobacter 2009; 14 (Suppl 1): 69-74.
5. Pellicano R, Ménard A, Rizzetto M, Mégraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect Dis 2008; 8: 254-60.
6. Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003; 5: 693-703.
7. Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5: 705-13.
8. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 2002; 359: 931-5.
9. Rothenbacher D, Winkler M, Gonser T, Adler G, Brenner H. Role of infected parents in transmission of Helicobacter pylori to their children. Pediatr Infect Dis J 2002; 21: 674-9.
10. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282: 2240-5.
11. Sontag SJ. Guilty as charged: bugs and drugs in gastric ulcer. Am J Gastroenterol 1997;92: 1255-61.
12. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002; 3: 97-104.
13. International Agency for Research on Cancer, World Health Organization 1994, Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on Evaluation of Carcinogenic Risks to Humans, IARC Press, Lyon, 60, 177.
14. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
15. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
16. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
17. Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 2009; 60: 3-21.
18. Ong SP, Duggan A. Eradication of Helicobacter pylori in clinical situations. Clin Exp Med 2004; 4: 30-8.
19. Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-65.
20. Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol 2009; 25: 549-56.
21. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
22. Niv Y. H. pylori recurrence after successful eradication. World J Gastroenterol 2008; 14: 1477-8.
23. Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009; 8: 1037-49.
24. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436-9.
25. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987; 82: 192-9.
26. Sobala GM, Crabtree JE, Dixon MF, et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991; 32: 1415-8.
27. Graham DY, Opekun AR, Osato MS, et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004; 53: 1235-43.
28. Ruggiero P, A Alloueche, R Rappuoli, G Del Giudice: Models for bacterial infectious diseases: Helicobacter pylori. Drug Discov Today: Dis Models 2004 1:95-100.
29. Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori. J Med Microbiol 1992; 37: 123-7.
30. Evans DJ Jr, Evans DG. Helicobacter pylori adhesins: review and perspectives. Helicobacter 2000; 5: 183-95.
31. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130: 188-206.
32. Schreiber S, Konradt M, Groll C, et al. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci USA 2004; 101: 5024-9.
33. Montecucco C, Rappuoli R. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat Rev Mol Cell Biol 2001; 2: 457-66.
34. Dubois A, Borén T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol 2007; 9: 1108-16.
35. Moran AP, Lindner B, Walsh EJ. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J Bacteriol 1997; 179: 6453-63.
36. Taylor DE, Rasko DA, Sherburne R, Ho C, Jewell LD. Lack of correlation between Lewis antigen expression by Helicobacter pylori and gastric epithelial cells in infected patients. Gastroenterology 1998; 115: 1113-22.
37. Nilsson C, Skoglund A, Moran AP, Annuk H, Engstrand L, Normark S. Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases. PLoS One 2008; 3: e3811.
38. Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 2006; 24: 4987-94.
39. Bergman MP, Engering A, Smits HH, et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DCSIGN. J Exp Med 2004; 200: 979-90.
40. Bergman M, Del Prete G, van Kooyk Y, Appelmelk B. Helicobacter pylori phase variation, immune modulation and gastric autoimmunity. Nat Rev Microbiol 2006; 4: 151-9.
41. Claeys D, Faller G, Appelmelk BJ, Negrini R, Kirchner T. The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology 1998; 115: 340-7.
42. Faller G, Steininger H, Kränzlein J, et al. Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut 1997; 41: 619-23.
43. Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198: 1147-56.
44. D'Elios MM, Appelmelk BJ, Amedei A, Bergman MP, Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10: 316-23.
45. Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991; 59: 2470-5.
46. Harris PR, Mobley HL, Perez-Perez GI, Blaser MJ, Smith PD. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology 1996; 111: 419-25.
47. Gobert AP, Mersey BD, Cheng Y, Blumberg DR, Newton JC, Wilson KT. Cutting edge: urease release by Helicobacter pylori stimulates macrophage inducible nitric oxide synthase. J Immunol 2002; 168: 6002-6.
48. Follmer C. Ureases as a target for the treatment of gastric and urinary infections. J Clin Pathol 2010; 63: 424-30.
49. Wassermann GE, Olivera-Severo D, Uberti AF, Carlini CR. Helicobacter pylori urease activates blood platelets through a lipoxygenase- mediated pathway. J Cell Mol Med 2010; 14: 2025-34.
50. Owen RJ, Slater ER, Xerry J, Peters TM, Teare EL, Grant A. Development of a scheme for genotyping Helicobacter pylori based on allelic variation in urease subunit genes. J Clin Microbiol 1998; 36: 3710-2.
51. Khan S, Karim A, Iqbal S. Helicobacter urease: niche construction at the single molecule level. J Biosci 2009; 34: 503-11.
52. Follmer C. Insights into the role and structure of plant ureases. Phytochemistry 2008; 69: 18-28.
53. Olivera-Severo D, Wassermann GE, Carlini CR. Ureases display biological effects independent of enzymatic activity: is there a connection to diseases caused by urease-producing bacteria? Braz J Med Biol Res 2006; 39: 851-61.
54. Montecucco C, De Bernard M. Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophilactivating protein (HP-NAP) virulence factors of Helicobacter pylori. Microbes Infect 2003; 5: 715-21.
55. Satin B, Del Giudice G, Della Bianca V, et al. The neutrophilactivating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000; 191: 1467-76.
56. Evans DJ Jr, Evans DG, Takemura T, et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995; 63: 2213-20.
57. Polenghi A, Bossi F, Fischetti F, et al. The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 2007; 178: 1312-20.
58. Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006; 116: 1092-1101.
59. Wang CA, Liu YC, Du SY, Lin CW, Fu HW. Helicobacter pylori neutrophil-activating protein promotes myeloperoxidase release from human neutrophils. Biochem Biophys Res Commun 2008; 377: 52-6.
60. Montemurro P, Nishioka H, Dundon WG, et al. The neutrophilactivating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. Eur J Immunol 2002; 32: 671-6.
61. Windle HJ, Ang YS, Athie-Morales V, McManus R, Kelleher D. Human peripheral and gastric lymphocyte responses to Helicobacter pylori NapA and AphC differ in infected and uninfected individuals. Gut 2005; 54: 25-32.
62. D'Elios MM, Amedei A, Cappon A, Del Prete G, de Bernard M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 2007; 50: 157-64.
63. Ceci P, Mangiarotti L, Rivetti C, Chiancone E. The neutrophilactivating Dps protein of Helicobacter pylori, HP-NAP, adopts a mechanism different from Escherichia coli Dps to bind and condense DNA. Nucleic Acids Res 2007: 35: 2247-56.
64. Lupetti P, Heuser JE, Manetti R, et al. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin. J Cell Biol 1996; 133: 801-7.
65. Gangwer KA, Mushrush DJ, Stauff DL, et al. Crystal structure of the Helicobacter pylori vacuolating toxin p55 domain. Proc Natl Acad Sci USA 2007; 104: 16293-8.
66. Torres VJ, Ivie SE, McClain MS, Cover TL. Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin. J Biol Chem 2005; 280: 21107-14.
67. Polk DB, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-14.
68. Rhead JL, Letley DP, Mohammadi M, et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology 2007; 133: 926-36.
69. Pagliaccia C, De Bernard M, Lupetti P, et al. The m2 form of the Helicobacter pylori cytotoxin has cell type-specific vacuolating activity. Proc Natl Acad Sci USA 1998; 95:10212-7.
70. Reyrat JM, Pelicic V, Papini E, Montecucco C, Rappuoli R, Telford JL. Towards deciphering the Helicobacter pylori cytotoxin. Mol Microbiol 1999; 34: 197-204.
71. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun1990 58: 603-10.
72. Harris PR, Cover TL, Crowe DR, et al. Helicobacter pylori cytotoxin induces vacuolation of primary human mucosal epithelial cells. Infect Immun 1996; 64: 4867-71.
73. Satin B, Norais N, Telford J, et al. Effect of Helicobacter pylori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation. J Biol Chem 1997 272: 25022-8.
74. Tombola F, Morbiato L, Del Giudice G, Rappuoli R, Zoratti M, Papini E. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001; 108: 929-37.
75. Telford JL, Ghiara P, Dell'Orco M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994; 179: 1653-58.
76. Molinari M, Salio M, Galli C, et al. Selective inhibition of Iidependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med 1998; 187: 135-40.
77. Petersen AM, Sørensen K, Blom J, Krogfelt KA. Reduced intracellular survival of Helicobacter pylori vacA mutants in comparison with their wild-types indicates the role of VacA in pathogenesis. FEMS Immunol Med Microbiol 2001; 30: 103-8.
78. Amieva MR, Salama NR, Tompkins LS, Falkow S. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 2002; 4: 677-90.
79. Terebiznik MR, Vazquez CL, Torbicki K, et al. Helicobacter pylori VacA toxin promotes bacterial intracellular survival in gastric epithelial cells. Infect Immun 2006; 74: 6599-614.
80. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003; 301: 1099-102.
81. Boncristiano M, Paccani SR, Barone S, et al. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med 2003; 198: 1887-97.
82. Supajatura V, Ushio H, Wada A, et al. Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol 2002; 168: 2603-7.
83. De Bernard M, Cappon A, Pancotto L, et al. The Helicobacter pylori VacA cytotoxin activates RBL-2H3 cells by inducing cytosolic calcium oscillations. Cell Microbiol 2005; 7: 191-8.
84. Velin D, Michetti P. Immunology of Helicobacter pylori infection. Digestion 2006; 73: 116-23.
85. Wang YH, Wu JJ, Lei HY. The autophagic induction in Helicobacter pylori-infected macrophage. Exp Biol Med 2009; 234: 171-80.
86. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
87. Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000; 191: 587-92.
88. Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-53.
89. Ogura K, Maeda S, Nakao M, et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 2000; 192: 1601-10.
90. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301.
91. Palli D, Masala G, Del Giudice G, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer 2007; 120: 859-67.
92. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321-33.
93. Hacker J, Carniel E. Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep 2001; 2: 376-81.
94. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci USA 2000; 97: 1263-8.
95. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683-6.
96. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430-4.
97. Stein M, Bagnoli F, Halenbeck R, Rappuoli R, Fantl WJ, Covacci A. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol 2002; 43: 971-80.
98. Yamazaki S, Yamakawa A, Ito Y, et al. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis 2003; 187: 334-7.
99. Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci USA 2005; 102: 16339-44.
100. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008; 105: 1003-8.
101. Suerbaum S, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol 2007; 5: 441-52.
102. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009; 119: 2475-87.
103. Viala J, Chaput C, Boneca IG, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-74.
104. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373-7.
105. Aspholm-Hurtig M, Dailide G, Lahmann M, et al. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 2004; 305: 519-22.
106. Yamaoka Y. Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis. World J Gastroenterol 2008; 14: 4265-72.
107. Styer CM, Hansen LM, Cooke CL, et al. Expression of the BabA adhesin during experimental infection with Helicobacter pylori. Infect Immun 2010; 78: 1593-600.
108. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci USA 2000; 97: 7533-8.
109. Dossumbekova A, Prinz C, Mages J, et al. Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis 2006; 194: 1346-55.
110. Rathinavelu S, Kao JY, Zavros Y, Merchant JL. Helicobacter pylori outer membrane protein 18 (Hp1125) induces dendritic cell maturation and function. Helicobacter 2005; 10: 424-32.
111. Petersson C, Forsberg M, Aspholm M, et al. Helicobacter pylori SabA adhesin evokes a strong inflammatory response in human neutrophils which is down-regulated by the neutrophil-activating protein. Med Microbiol Immunol 2006; 195: 195-206.
112. Mahdavi J, Sondén B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-8.
113. Yamaoka Y. Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease. J Infect Dev Ctries 2008; 2: 174-81.
114. Lee CK, Weltzin R, Thomas WD Jr, et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995; 172: 161-72.
115. Ferrero RL, Thiberge JM, Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology 1997; 113: 185-94.
116. Tosi MF, Czinn SJ. Opsonic activity of specific human IgG against Helicobacter pylori. J Infect Dis 1990; 162: 156-62.
117. Cover TL, Cao P, Murthy UK, Sipple MS, Blaser MJ. Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori. J Clin Invest 1992; 90: 913-8.
118. Bogstedt AK, Nava S, Wadström T, Hammarström L. Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin Exp Immunol 1996; 105: 202-4.
119. Ermak TH, Giannasca PJ, Nichols R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188: 2277-88.
120. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG. Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell Immunol 1999; 191: 74-80.
121. Pappo J, Torrey D, Castriotta L, Savinainen A, Kabok Z, Ibraghimov A. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun 1999; 67: 337-41.
122. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacterspecific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol 1996; 156: 4729-38.
123. Rossi G, Fortuna D, Pancotto L, et al. Immunohistochemical study of lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with Helicobacter pylori. Infect Immun 2000; 68: 4769-72.
124. Mattapallil JJ, Dandekar S, Canfield DR, Solnick JV. A predominant Th1 type of immune response is induced early during acute Helicobacter pylori infection in rhesus macaques. Gastroenterology 2000; 118: 307-15.
125. D'Elios MM, Manghetti M, De Carli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997; 158: 962-7.
126. Wen S, Felley CP, Bouzourene H, Reimers M, Michetti P, Pan-Hammarström Q. Inflammatory gene profiles in gastric mucosa during Helicobacter pylori infection in humans. J Immunol 2004; 172: 2595-606.
127. Bimczok D, Clements RH, Waites KB, et al. Human primary gastric dendritic cells induce a Th1 response to H. pylori. Mucosal Immunol 2010; 3: 260-9.
128. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 1997; 113: 1848-57.
129. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000; 165: 1022-9.
130. Saldinger PF, Porta N, Launois P, et al. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 1998; 115: 891-7.
131. Fox JG, Beck P, Dangler CA, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000; 6: 536-42.
132. Akhiani AA, Pappo J, Kabok Z, et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002; 169: 6977-84.
133. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 2003; 71: 910-21.
134. Taylor JM, Ziman ME, Fong J, Solnick JV, Vajdy M. Possible correlates of long-term protection against Helicobacter pylori fol lowing systemic or combinations of mucosal and systemic immunizations. Infect Immun 2007; 75: 3462-9.
135. Akhiani AA, Schön K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J Immunol 2004; 173: 3348-56.
136. Yamamoto T, Kita M, Ohno T, Iwakura Y, Sekikawa K, Imanishi J. Role of tumor necrosis factor-alpha and interferon-gamma in Helicobacter pylori infection. Microbiol Immunol 2004; 48: 647-54.
137. Lehmann FS, Terracciano L, Carena I, et al. In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis. Am J Physiol Gastrointest Liver Physiol 2002; 283: G481-8.
138. D'Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and cytokines: the "dangerous liaisons". FEMS Immunol Med Microbiol 2005; 44: 113-9.
139. D'Elios MM, Amedei A, Del Prete G. Helicobacter pylori antigenspecific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes Infect 2003; 5: 723-30.
140. Garhart CA, Redline RW, Nedrud JG, Czinn SJ. Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice. Infect Immun 2002; 70: 3529-38.
141. Raghavan S, Svennerholm AM, Holmgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 2002; 70: 4621-7.
142. Shi Y, Liu XF, Zhuang Y, et al. Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol 2010; 184: 5121-9.
143. Velin D, Favre L, Bernasconi E, et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009; 136: 2237-2246.
144. Mandell L, Moran AP, Cocchiarella A, et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004; 72: 6446-54.
145. Smith MF Jr, Mitchell A, Li G, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pyloriinduced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003; 278: 32552-60.
146. Ding SZ, Torok AM, Smith MF Jr, Goldberg JB. Toll-like receptor 2-mediated gene expression in epithelial cells during Helicobacter pylori infection. Helicobacter 2005; 10: 193-204.
147. Kawahara T, Kuwano Y, Teshima-Kondo S, et al. Toll-like receptor4 regulates gastric pit cell responses to Helicobacter pylori infection. J Med Invest 2001; 48: 190-7.
148. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
149. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905-12.
150. Kaparakis M, Philpott DJ, Ferrero RL. Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol 2007; 85: 495-502.
151. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 23: 398-402.
152. Shanks AM, El-Omar EM. Helicobacter pylori infection, host genetics and gastric cancer. J Dig Dis 2009; 10: 157-64.
153. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
154. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloidderived suppressor cells in mice. Cancer Cell 2008; 14: 408-19.
155. Yea SS, Yang YI, Jang WH, Lee YJ, Bae HS, Paik KH. Association between TNF-alpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol 2001; 54: 703-6.
156. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-71.
157. Partida-Rodríguez O, Torres J, Flores-Luna L, et al. Polymorphisms in TNF and HSP-70 show a significant association with gastric cancer and duodenal ulcer. Int J Cancer 2010; 126: 1861-8.
158. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003; 104: 617-23.
159. Hall TJ. Role of hsp70 in cytokine production. Experientia 1994; 50: 1048-53.
160. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-69.
161. Stoicov C, Fan X, Liu JH, et al. T-bet knockout prevents Helicobacter felis-induced gastric cancer. J Immunol 2009; 183: 642-9.
162. Ohyauchi M, Imatani A, Yonechi M, et al. The polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005; 54: 330-5.
163. Liu L, Zhuang W, Wang C, Chen Z, Wu XT, Zhou Y. Interleukin-8 -251 A/T gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiological studies. Cytokine 2010; 50: 328-34.
164. McLean MH, El-Omar EM. Genetic aspects of inflammation. Curr Opin Pharmacol 2009; 9: 370-4.
165. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori- specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122-7.
166. D'Elios MM, Amedei A, Manghetti M, et al. Impaired T-cell regulation of B-cell growth in Helicobacter pylori-related gastric lowgrade MALT lymphoma. Gastroenterology 1999; 117: 1105-12.
167. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
168. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
169. Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003; 71: 1755-62.
170. Lundgren A, Trollmo C, Edebo A, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4+ T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun 2005; 73: 5612-9.
171. Lundgren A, Strömberg E, Sjöling A, et al. Mucosal FOXP3- expressing CD4+CD25high regulatory T cells in Helicobacter pyloriinfected patients. Infect Immun 2005; 73: 523-31.
172. Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol 2003; 132: 393-400.
173. Rad R, Brenner L, Bauer S, et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006; 131: 525-37.
174. Raghavan S, Holmgren J. CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol Med Microbiol 2005; 44: 121-7.
175. Strömberg E, Edebo A, Lundin BS, et al. Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. Clin Exp Immunol 2005; 140: 117-25.
176. Kao JY, Zhang M, Miller MJ, et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 2010; 138: 1046-54.
177. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999; 284: 1328-33.
178. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007; 445: 915-8.
179. Falush D, Wirth T, Linz B, et al. Traces of human migrations in Helicobacter pylori populations. Science 2003; 299: 1582-5.
180. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007-13.
181. Moon A, Solomon A, Beneck D, Cunningham-Rundles S. Positive association between Helicobacter pylori and gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2009; 49: 283-8.